Kimia Farma and Pfizer Indonesia Collaborate to Boost Pneumonia Vaccination
PT Kimia Farma Diagnostika has partnered with PT Pfizer Indonesia to enhance the vaccination program in Indonesia, focusing on pneumonia. This partnership aims to raise public awareness about the importance of immunization against this life-threatening disease, which continues to be one of the leading causes of mortality and hospitalizations across various age groups in the country.
The CEO of PT Kimia Farma Diagnostika, Arie Genipa Suhendi, stated that this collaboration represents a vital step for both partners, as it not only contributes to providing integrated healthcare services but also actively participates in disease prevention and improving the quality of life for Indonesians. The joint efforts are aimed at strengthening national vaccination programs by providing access to effective and modern health solutions.
Pneumonia, as a highly infectious disease, poses serious health challenges, especially among infants and the elderly, leading to a high number of hospitalizations. Vaccination against this disease can significantly reduce risks for vulnerable groups, including pilgrims during Hajj and Umrah.
This partnership not only aims to improve national health but also seeks to support sustainable, science-based healthcare systems, making them more accessible to the population. PT Kimia Farma Diagnostika and Pfizer Indonesia believe that their continued efforts will have a lasting positive impact, helping to create stronger and more engaged communities.
